Ratings Safe Fertility Group

Equities

End-of-day quote Thailand S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
22.8 ^THB	-1.30%		+1.79%	+24.59%

May. 02	41,792,822 Ordinary Shares of Safe Fertility Group Public Company Limited are subject to a Lock-Up Agreement Ending on 2-MAY-2024.	CI
Apr. 26	Safe Fertility Group Public Company Limited Approves Dividend, Payable on May 24, 2024	CI

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts covering this company mostly recommend stock overweighting or purchase.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

The firm trades with high earnings multiples: 24.92 times its 2024 earnings per share.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

	1st Jan change	Capi.	ESG Refinitiv
SAFE FERTILITY GROUP	+24.59%	190M	-
HCA HEALTHCARE, INC.	+17.63%	83.4B	C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+2.04%	27.04B	C+
LABCORP HOLDINGS INC.	-11.48%	16.96B	B
FRESENIUS SE & CO. KGAA	-1.57%	16.86B	A-
QUEST DIAGNOSTICS INCORPORATED	+2.89%	15.76B	A-
REDE D'OR SÃO LUIZ S.A.	+1.25%	12.76B	B-
NATERA, INC.	+73.23%	13.33B	C-
TENET HEALTHCARE CORPORATION	+72.58%	12.74B	C+
FRESENIUS MEDICAL CARE AG	+2.08%	12.32B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality